Headache News

Women who developed migraine with aura had a higher incidence rate of CVD vs. women who developed migraine without aura or had no migraine, according to a cohort study published in JAMA.

In this video, Christina L. Szperka, MD, MSCE, director of the Pediatric Headache Program and a pediatric neurologist at Children’s Hospital of Philadelphia, discusses migraine care and treatment strategies in the era of COVID-19.

Patients with migraine who switched from Aimovig to Emgality to treat their headaches reported similar improvements between the two treatments, according to research presented at the virtual American Headache Society Annual Meeting.

An intranasal dry powder formulation of dihydroergotamine, called STS101, outperformed other formulations of the drug for the treatment of migraine pain, according to researchers.

Ubrogepant provided pain relief to patients with migraine in a real-world setting, according to preliminary results of an ongoing study evaluating recently approved treatments.

DFN-15, a 120 mg oral celecoxib solution, was shown to be safe and effective among patients with episodic migraine in two phase 3 studies presented at the American Headache Society Annual Meeting.

Treating patients who have chronic migraine with both onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibody medications could reduce their monthly migraine days by an additional 5.6 days than if they had just received onabotulinumtoxinA alone, according to research presented at the American Headache Society Annual Meeting.

Yoga as an add-on therapy was superior to medical therapy alone for adults with migraine, according to a prospective, randomized, open-label trial published in Neurology, the medical journal of the American Academy of Neurology.

New real-world data show a monthly self-injection of erenumab, a preventive migraine treatment, reduced migraine intensity and the incidence of migraine attacks in most patients, according to a press release from the manufacturer.

A new FDA-funded registry developed by researchers at the Duke Clinical Research Institute and partners could help answer important questions about an understudied area in medicine: pediatric migraine.